Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

Tait D. Shanafelt; John C. Byrd; Betsy LaPlant; Clive S. Zent; Tim Call; Charla Secreto; Michael R. Grever; Thomas S. Lin; Neil E. Kay

doi:10.1111/j.1365-2141.2009.07811.x

Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

Tait D. Shanafelt, John C. Byrd, Betsy LaPlant, Clive S. Zent, Tim Call, Charla Secreto, Michael R. Grever, Thomas S. Lin, Neil E. Kay

Hematology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti- [thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.

Original language	English (US)
Pages (from-to)	660-664
Number of pages	5
Journal	British journal of haematology
Volume	146
Issue number	6
DOIs	https://doi.org/10.1111/j.1365-2141.2009.07811.x
State	Published - 2009

Keywords

Angiogenesis
Chronic lymphocytic leukaemia
Prognostic factors.
Therapy
Vascular endothelial growth factor

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2009.07811.x

Cite this

@article{98ed18ec842149a880ba75f237bd4c7a,

title = "Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia",

abstract = "Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti- [thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.",

keywords = "Angiogenesis, Chronic lymphocytic leukaemia, Prognostic factors., Therapy, Vascular endothelial growth factor",

author = "Shanafelt, {Tait D.} and Byrd, {John C.} and Betsy LaPlant and Zent, {Clive S.} and Tim Call and Charla Secreto and Grever, {Michael R.} and Lin, {Thomas S.} and Kay, {Neil E.}",

year = "2009",

doi = "10.1111/j.1365-2141.2009.07811.x",

language = "English (US)",

volume = "146",

pages = "660--664",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

AU - Shanafelt, Tait D.

AU - Byrd, John C.

AU - LaPlant, Betsy

AU - Zent, Clive S.

AU - Call, Tim

AU - Secreto, Charla

AU - Grever, Michael R.

AU - Lin, Thomas S.

AU - Kay, Neil E.

PY - 2009

Y1 - 2009

N2 - Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti- [thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.

AB - Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti- [thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.

KW - Angiogenesis

KW - Chronic lymphocytic leukaemia

KW - Prognostic factors.

KW - Therapy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=77449133325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449133325&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07811.x

DO - 10.1111/j.1365-2141.2009.07811.x

M3 - Article

C2 - 19604237

AN - SCOPUS:77449133325

SN - 0007-1048

VL - 146

SP - 660

EP - 664

JO - British journal of haematology

JF - British journal of haematology

IS - 6

ER -

Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this